Analyst Group

Analyst Group Comment on Circio’s In Vivo Cell Therapy Collaboration with Full Circles Therapeutics

Källa: MFN
Neutral

Sammanfattning

Circio Holding ASA ingår ett forskningssamarbete med Full Circles Therapeutics Inc. för att utveckla en ny plattform för in vivo cellterapi. Samarbetet kombinerar bolagens teknologier för att skapa en icke-viral, icke-integrerande och immunologiskt tyst plattform. Inga finansiella villkor har offentliggjorts.

Analys

Samarbetet med Full Circles Therapeutics är tekniskt logiskt och syftar till att adressera begränsningar i befintliga in vivo cellterapier gällande hållbarhet och möjligheten till upprepade doser. Då projektet befinner sig i preklinisk fas och inga finansiella villkor är kända, utgör det en option snarare än en omedelbar värdedrivare. Kommande uppdateringar kring R&D och data för hjärta och CNS, samt CAR-T programmet, blir viktiga.

Insikter

  • • Samarbetet syftar till att förbättra hållbarhet och möjligheten till upprepade doser i cellterapier.
  • • Fokus ligger på att utveckla en icke-viral, icke-integrerande och immunologiskt tyst plattform.
  • • Nästa H1-26 rapport och R&D-uppdatering kommer att ge viktig data om hjärta, CNS och CAR-T programmet.
Påverkan · Neutral · 3/10
Liten påverkan
NegativNeutralPositiv
−100+10

Circio Holding ASA (“Circio” or “the Company”) announced, on the 26th of August 2026, a research collaboration with Full Circles Therapeutics Inc. (“Full Circles”), a Boston-based developer of non-viral, immune-evasive DNA vector technology. The parties will combine circVec with Full Circles’ C4DNA platform, an engineered circular single-stranded DNA (cssDNA) vector designed to avoid innate immune recognition, to establish a non-viral, non-integrating and immune-silent platform for in vivo cell therapy. Full Circles will design and manufacture C4DNA vectors carrying circVec inserts, which Circio will then evaluate in vitro and in vivo for delivery, expression and immunogenicity. No financial terms are disclosed.

Circio Holding ASA (“Circio” or “the Company”) announced, on the 26th of August 2026, a research collaboration with Full Circles Therapeutics Inc. (“Full Circles”), a Boston-based developer of non-viral, immune-evasive DNA vector technology. The parties will combine circVec with Full Circles’ C4DNA platform, an engineered circular single-stranded DNA (cssDNA) vector designed to avoid innate immune recognition, to establish a non-viral, non-integrating and immune-silent platform for in vivo cell therapy. Full Circles will design and manufacture C4DNA vectors carrying circVec inserts, which Circio will then evaluate in vitro and in vivo for delivery, expression and immunogenicity. No financial terms are disclosed.

In summary, Analyst Group views the Full Circles collaboration as a technically coherent addition to Circio’s in vivo cell therapy work, pointing toward the combination of durability and re-dosability that in vivo cell therapy has so far lacked. It nevertheless remains preclinical and without disclosed terms, and cell therapy continues to represent an optionality layer rather than a near-term value driver. The H1-26 report will be published on the 31st of August, followed by an R&D and corporate update webcast on the 1st of September, which is set to include new in vivo data in heart and CNS as well as an update on the CAR-T program.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.